Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.

Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level. Jpn J Clin Oncol. 2011 Aug; 41(8):1023-30.

View in: PubMed

subject areas

Aged
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell
Disease-Free Survival
Female
Humans
Immunologic Factors
Interferon-alpha
Interleukin-2
Kaplan-Meier Estimate
Kidney Neoplasms
Lung Neoplasms
Male
Middle Aged
Prognosis
Proportional Hazards Models
Prospective Studies
Sodium
Treatment Outcome

authors with profiles

Yusuke Nakamura